Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03089658
Previous Study | Return to List | Next Study

Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03089658
Expanded Access Status : Approved for marketing
First Posted : March 24, 2017
Last Update Posted : October 9, 2019
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Merck KGaA, Darmstadt, Germany

Tracking Information
First Submitted Date March 20, 2017
First Posted Date March 24, 2017
Last Update Posted Date October 9, 2019
 
Descriptive Information
Brief Title Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Brief Summary Expanded access to Avelumab solution for infusion will be made available for adult patients with mMCC whose disease has progressed after receiving at least one prior chemotherapy.
Detailed Description Not Provided
Study Type Expanded Access
Intervention Drug: Avelumab
Avelumab should be administered intravenously as per the recommended dose. Administration of Avelumab should continue according to the recommended schedule until disease progression or unacceptable toxicity.
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status Approved for marketing
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries France
Removed Location Countries  
 
Administrative Information
NCT Number NCT03089658
Responsible Party Merck KGaA, Darmstadt, Germany
Study Sponsor Merck KGaA, Darmstadt, Germany
Collaborators Pfizer
Investigators Not Provided
PRS Account Merck KGaA, Darmstadt, Germany
Verification Date October 2019